Free Trial
NASDAQ:ELVN

Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Enliven Therapeutics logo
$20.52 +0.01 (+0.05%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Enliven Therapeutics Stock (NASDAQ:ELVN)

Key Stats

Today's Range
$19.96
$20.60
50-Day Range
$14.91
$22.46
52-Week Range
$13.30
$30.03
Volume
91,479 shs
Average Volume
259,370 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.33
Consensus Rating
Buy

Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

ELVN MarketRank™: 

Enliven Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 542nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Enliven Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enliven Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.95) to ($2.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enliven Therapeutics is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enliven Therapeutics is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enliven Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Enliven Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    23.47% of the float of Enliven Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Enliven Therapeutics has a short interest ratio ("days to cover") of 28.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enliven Therapeutics has recently increased by 2.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Enliven Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Enliven Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    23.47% of the float of Enliven Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Enliven Therapeutics has a short interest ratio ("days to cover") of 28.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enliven Therapeutics has recently increased by 2.34%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Enliven Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Enliven Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,331,288.00 in company stock.

  • Percentage Held by Insiders

    29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enliven Therapeutics' insider trading history.
Receive ELVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELVN Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Enliven Therapeutics: Awaiting Additional Trial Data
See More Headlines

ELVN Stock Analysis - Frequently Asked Questions

Enliven Therapeutics' stock was trading at $22.50 at the beginning of the year. Since then, ELVN shares have decreased by 10.2% and is now trading at $20.21.
View the best growth stocks for 2025 here
.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) posted its earnings results on Thursday, March, 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The firm earned $0.03 million during the quarter.

Top institutional shareholders of Enliven Therapeutics include Bank of New York Mellon Corp (0.19%), Rhumbline Advisers (0.11%), China Universal Asset Management Co. Ltd. (0.02%) and New York State Common Retirement Fund (0.02%). Insiders that own company stock include Joseph P Lyssikatos, Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Richard A Heyman, Benjamin Hohl and Rahul D Ballal.
View institutional ownership trends
.

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
3/13/2025
Today
5/05/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELVN
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.33
High Stock Price Target
$42.00
Low Stock Price Target
$39.00
Potential Upside/Downside
+99.6%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.97 per share
Price / Book
3.39

Miscellaneous

Free Float
34,592,000
Market Cap
$991.62 million
Optionable
Optionable
Beta
1.07
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ELVN) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners